Despite advances in many drug research paradigms, including DNA sequencing, high throughput screening, and CRISPR, success rates in drug development have remained largely unchanged. An estimated $2.6B and 12 years are spent bringing a drug to market, due largely to the industry’s reliance on ineffective animal models. The gap between the benchtop and bedside is wide, but Organ-on-a-Chip technology and microphysiological systems (MPS) show promise to bridge the divide. Hype surrounding this revolutionary technology is high. Expectations range from replacing animal testing and clinical trials in a dish to personalized medicine, but what can we realistically expect in the next 3-5 years?
This panel will summarize the potential for novel alternatives to animal testing, as well as define limitations and the need to set expectations. Based on the experiences of the panel, the current state of industry adoption, regulatory acceptance, and clinical applications will be highlighted.

Ability Level: Advanced

Session ID: 502391